United Therapeutics Corpo... (UTHR)
370.88
0.30 (0.08%)
At close: Feb 18, 2025, 3:59 PM
372.83
0.52%
After-hours: Feb 18, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 320 |
| Market Cap | 16.56B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 22.75 |
| PE Ratio (ttm) | 16.3 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 385.17 |
| Volume | 331,146 |
| Avg. Volume (20D) | 309,681 |
| Open | 371.88 |
| Previous Close | 370.58 |
| Day's Range | 366.00 - 374.35 |
| 52-Week Range | 213.75 - 417.82 |
| Beta | undefined |
About UTHR
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin a...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 17, 1999
Employees 1,168
Stock Exchange NASDAQ
Ticker Symbol UTHR
Website https://www.unither.com
Analyst Forecast
According to 13 analyst ratings, the average rating for UTHR stock is "Strong Buy." The 12-month stock price forecast is $380, which is an increase of 2.46% from the latest price.
Buy 76.92%
Hold 15.38%
Sell 7.69%
Next Earnings Release
United Therapeutics Corporation is scheduled to release its earnings on Mar 4, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
+3.04%
United Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
6 months ago
-7.18%
United Therapeutics shares are trading lower after the company reported mixed Q2 financial results.
